The immune profiling analysis of peripheral blood reveals an increased abundance of LAG-3hiPD-1hi memory CD4+ T cell subset in relapsed cholangiocarcinoma patients after gemcitabine plus cisplatin therapy, which provided a basis for the study of immune checkpoint inhibitors for CCA (170). The gene discussed is CD4; the disease is cholangiocarcinoma.